Thymic carcinoma
Thymic carcinoma is the aggressive kind of thymic epithelial tumour, a cancer of the thymus that behaves like carcinoma elsewhere and has often spread when found. Surgery is attempted when possible, carboplatin with paclitaxel is the usual chemotherapy, and sunitinib, lenvatinib and the PD-1 antibody pembrolizumab have shown responses in trials, with lenvatinib approved in Japan.
Overview
Thymic carcinoma differs from thymoma in every way that matters: its cells are overtly malignant, it lacks the immature T lymphocytes and the organotypic features of thymoma, it is rarely associated with myasthenia gravis, and it presents with local invasion, pleural spread or distant metastases in most patients. Squamous cell carcinoma is the commonest subtype, followed by lymphoepithelioma-like, basaloid, mucoepidermoid, sarcomatoid and NUT carcinoma (covered on its own page); thymic neuroendocrine carcinomas are classified separately. KIT mutations occur in about a tenth of thymic carcinomas, mostly squamous, and respond to imatinib in case series, and TP53, CDKN2A and epigenetic regulator mutations are common; PD-L1 is often highly expressed.
Complete resection is attempted for localised disease, followed by postoperative radiotherapy, and chemotherapy is given before surgery for borderline tumours. For advanced disease the guidelines favour carboplatin and paclitaxel, which produced responses in about a fifth of patients with thymic carcinoma in prospective series, with CAP or platinum-etoposide as alternatives. After platinum, three phase 2 trials define the options: sunitinib (Lancet Oncology 2015) produced responses in about a quarter of 23 patients with thymic carcinoma; lenvatinib in the Japanese REMORA trial (Lancet Oncology 2020) produced responses in 38 percent of 42 patients and was approved in Japan in 2021; and pembrolizumab (Lancet Oncology 2018) produced responses in 22.5 percent of 40 patients with durable benefit but severe immune-related adverse events, including myocarditis, in 15 percent, a rate high enough that PD-1 antibodies are used only with monitoring and are avoided in thymoma. Newer agents in trials include the multikinase inhibitor KC1036, the TROP2 antibody-drug conjugate sacituzumab tirumotecan, ramucirumab with carboplatin and paclitaxel, and CAR-NK cells against CD30 or mesothelin.
State of the art
- Carboplatin and paclitaxel is the accepted first-line regimen on prospective phase 2 evidence.
- Lenvatinib is the first drug approved anywhere specifically for thymic carcinoma.
- Pembrolizumab gives durable responses in a fifth of patients but at a real risk of myocarditis.
Red cards
From the labels and guidelines behind the standard of care. Your team's thresholds win.- Emergency services nowBleeding or bruising
Bleeding that will not stop, black or bloody stools, or unexplained bruising when platelets are expected to be low.
- Emergency services nowFainting or palpitations
Fainting, near-fainting, or an irregular or racing heartbeat; several kinase inhibitors prolong the QT interval and the labels require ECG and electrolyte monitoring.
- Emergency services nowBowel perforation
Sudden severe abdominal pain, a hard or very tender abdomen, or abdominal pain with vomiting and fever. Boxed warning for gastrointestinal perforation on bevacizumab.
- Emergency services nowHypophysitis or adrenal crisis
Persistent headache with extreme tiredness, nausea, dizziness on standing or low blood pressure. Vomiting, severe weakness or collapse is adrenal crisis.
- Check before combiningSunitinib with Lenvatinib: major interaction
QT: both Sunitinib and Lenvatinib prolong the QT interval (known and known risk).. Avoid other QT-prolonging drugs where possible; check ECG and correct potassium and magnesium before and during treatment.
- Check before combiningFood and drink: Doxorubicin
Cumulative dose: risk rises steeply above 400-550 mg/m² (see the anthracycline calculator).
See all on the product pages:CarboplatinCisplatinCyclophosphamideDoxorubicinImatinibLenvatinibPaclitaxel / nab-paclitaxelPembrolizumabSunitinib·Printable cards in the navigator
Anatomy and lymph node drainage
- Central airways (squamous, small-cell)
- Periphery (adenocarcinoma)
- Apex (Pancoast)
- Pleura (mesothelioma)
- Thymus (anterior mediastinum)
- Nodes: hilar (N1)
- Nodes: mediastinal (N2)
- Nodes: supraclavicular (N3)
Central tumours arise in the large airways, peripheral ones in the alveoli; both drain to hilar then mediastinal nodes, and the pleural lining is a separate cancer site.
- Central airways (squamous, small-cell)Thymic squamous cell carcinoma (the commonest form; KIT mutations in a subset)
- Periphery (adenocarcinoma)Basaloid, mucoepidermoid and adenocarcinoma of the thymus · Advanced or metastatic thymic carcinoma (carboplatin-paclitaxel, then kinase inhibitors or pembrolizumab)
- Apex (Pancoast)
- Pleura (mesothelioma)Sarcomatoid thymic carcinoma
- Thymus (anterior mediastinum)Thymic squamous cell carcinoma (the commonest form; KIT mutations in a subset) · Lymphoepithelioma-like thymic carcinoma (EBV-associated in some) · Basaloid, mucoepidermoid and adenocarcinoma of the thymus · Sarcomatoid thymic carcinoma · Resectable thymic carcinoma (surgery and postoperative radiotherapy) · Advanced or metastatic thymic carcinoma (carboplatin-paclitaxel, then kinase inhibitors or pembrolizumab)
- hilar (N1)
- mediastinal (N2)
- supraclavicular (N3)
Same organ: Non-small-cell lung cancer, Lung cancer (all types), Small-cell lung cancer, Mesothelioma, Pleural mesothelioma, Thymoma and thymic carcinoma, Childhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours), Inflammatory myofibroblastic tumour (IMT), EGFR-mutated non-small-cell lung cancer, ALK-positive non-small-cell lung cancer, KRAS G12C-mutant non-small-cell lung cancer, ROS1-positive non-small-cell lung cancer, MET exon 14 and MET-amplified non-small-cell lung cancer, RET fusion-positive non-small-cell lung cancer, BRAF V600E-mutant non-small-cell lung cancer, HER2-mutant non-small-cell lung cancer, NTRK fusion-positive non-small-cell lung cancer, PD-L1-high non-small-cell lung cancer without a driver mutation, Resectable stage I to III non-small-cell lung cancer, Unresectable stage III non-small-cell lung cancer, Limited-stage small-cell lung cancer, Extensive-stage small-cell lung cancer, Lung neuroendocrine tumours (typical and atypical carcinoid), Thymoma (WHO types A, AB, B1, B2 and B3)
About a fifth of thymic epithelial tumours; usually found at an advanced stage with invasion of the mediastinum or spread to pleura, nodes and distant organs, and rarely tied to myasthenia gravis.
Cases by country
No country-level case numbers. This cancer is not mapped to a GLOBOCAN site.
One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.
Complete resection with thymectomy and involved structures; postoperative radiotherapy for all stages of thymic carcinoma; chemotherapy considered after incomplete resection.
Induction chemotherapy (carboplatin-paclitaxel or CAP) followed by surgery or radiotherapy according to response.
Carboplatin and paclitaxel; CAP or platinum-etoposide as alternatives.
Sunitinib; lenvatinib (approved in Japan, REMORA); pembrolizumab with cardiac and autoimmune monitoring; everolimus; imatinib for KIT-mutant tumours.
KC1036, sacituzumab tirumotecan, CAR-NK cells, ramucirumab combinations.
Subtypes & biomarkers
top- Thymic squamous cell carcinoma (the commonest form; KIT mutations in a subset)
- Lymphoepithelioma-like thymic carcinoma (EBV-associated in some)
- Basaloid, mucoepidermoid and adenocarcinoma of the thymus
- Sarcomatoid thymic carcinoma
- Resectable thymic carcinoma (surgery and postoperative radiotherapy)
- Advanced or metastatic thymic carcinoma (carboplatin-paclitaxel, then kinase inhibitors or pembrolizumab)
- Histological subtype and CD5, CD117 (KIT) and p63 immunohistochemistry
- TNM and Masaoka-Koga stage
- Completeness of resection
- KIT mutation (imatinib-responsive subset)
- PD-L1 expression (high in many; not required for pembrolizumab)
- Baseline troponin and autoimmune screen before PD-1 therapy
How often this target appears
- 1999WHO classification separates thymic carcinoma (then type C) from thymoma
- 2004KIT mutations and imatinib responses described in thymic carcinoma
- 2015Sunitinib phase 2 reports responses in thymic carcinoma after platinum
- 2018Pembrolizumab phase 2 in thymic carcinoma: 22.5 percent response, 15 percent severe immune toxicity
- 2020REMORA: lenvatinib 38 percent response rate in thymic carcinoma
- 2021Lenvatinib approved in Japan for unresectable thymic carcinoma
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
All 7 changes by month →- 2026-09-18This recordThymic carcinomaFacts on this page last checked
When this page itself was last checked or edited.
- 2021MilestoneLenvatinibLenvatinib approved in Japan for unresectable thymic carcinoma
A milestone in how this cancer is treated.
- 2020MilestoneLenvatinibREMORA: lenvatinib 38 percent response rate in thymic carcinoma
A milestone in how this cancer is treated.
- 2018MilestonePembrolizumabPembrolizumab phase 2 in thymic carcinoma: 22.5 percent response, 15 percent severe immune toxicity
A milestone in how this cancer is treated.
- 2015MilestoneSunitinibSunitinib phase 2 reports responses in thymic carcinoma after platinum
A milestone in how this cancer is treated.
- 2004MilestoneImatinibKIT mutations and imatinib responses described in thymic carcinoma
A milestone in how this cancer is treated.
What is in development for Thymic carcinoma, drawn from the whole corpus: 5 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Drugs in phase 3 · 1
Drugs in phase 2 · 1
Trials under way · 3
- Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma · phase 2 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- A Study of KC1036 in Patients with Advanced Thymic Tumors · phase 2 · Beijing Konruns Pharmaceutical Co., Ltd.
- Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma · phase 1/2 · Beijing Biotech
Open problems and what is being done
No randomised trial has compared any two regimens in thymic carcinoma.
The sequence of kinase inhibitors and immunotherapy is unstudied.
Predicting which patients will develop myocarditis on PD-1 antibodies is not yet possible.
Long-term survival in metastatic disease remains poor.
and how the field plans to fix it →What is being done about thisAdvanced and metastatic diseaseAvailable now- IMRT / IGRT (modern external beam)Standard of care
In trialsIdeas and roadmapsNothing recorded yet.
Also on OnCo: Atlas of advanced disease · Invasion and metastasis.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Expert centres
topExpert centres
Houston · cancer center | United States | 0 | 6,724 | 95,007 | #2 | ||
Seoul · hospital | South Korea | none recorded | 0 | 1,312 | 17,172 | #3 | |
Rochester, MN · hospital | United States | 0 | 4,511 | 44,748 | #5 | ||
Baltimore · cancer center | United States | 0 | 2,955 | 41,449 | #10 | ||
Berlin · university | Germany | none recorded | 0 | 1,563 | 17,749 | #12 | |
Boston · hospital | United States | 0 | 3,582 | 54,857 | #16 | ||
Heidelberg · cancer center | Germany | none recorded | 0 | 3,456 | 45,745 | #18 | |
Cleveland · hospital | United States | 0 | 2,264 | 29,412 | #20 | ||
Paris · cancer center | France | none recorded | 0 | 1,065 | 15,111 | #21 | |
Seoul · hospital | South Korea | none recorded | 0 | 464 | 3,248 | #22 | |
Manchester · cancer center | United Kingdom | none recorded | 0 | 104 | 2,145 | #23 | |
Amsterdam · cancer center | Netherlands | none recorded | 0 | 1,451 | 25,873 | #45 | |
Shanghai · cancer center | China | none recorded | 0 | 1,678 | 18,354 | #55 | |
Philadelphia · cancer center | United States | 0 | 3,148 | 54,267 | - | ||
Ann Arbor, MI · cancer center | United States | 0 | 2,991 | 29,686 | - |
These are the things we can measure; they are not a ranking of quality. Each column is a field on the institution record or a count over what OnCo has linked; a centre that treats many patients with Thymic carcinoma but is thinly recorded here will look small.
Not known: OnCo holds no case-volume or outcome figures for centres, so none are shown. Where a national audit or registry publishes them, the centre's page links to it. Default order: Newsweek rank, then trials for this cancer, then research output.
Questions to ask
topQuestions to ask your oncologist about Thymic carcinoma
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Why: Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example Histological subtype and CD5, CD117and p63 immunohistochemistry, TNM and Masaoka-Koga stage, Completeness of resection, KIT mutation, PD-L1 expression), and what were the results?Why: These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Why: Recognised subtypes for this cancer include Thymic squamous cell carcinoma, Lymphoepithelioma-like thymic carcinoma, Basaloid, mucoepidermoid and adenocarcinoma of the thymus.
- Is germline (inherited) genetic testing recommended for me or my family?Why: Inherited variants can change treatment and matter for relatives.
Resectable disease
- For my situation (resectable disease), which of the standard options do you recommend and why?Why: Guideline options include: Complete resection with thymectomy and involved structures; postoperative radiotherapy for all stages of thymic carcinoma; chemotherapy considered after incomplete resection.
Borderline resectable
- For my situation (borderline resectable), which of the standard options do you recommend and why?Why: Guideline options include: Induction chemotherapy (carboplatin-paclitaxel or CAP) followed by surgery or radiotherapy according to response.
- Am I a candidate for Carboplatin, Paclitaxel / nab-paclitaxel, Cisplatin or related drugs, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
Advanced, first line
- For my situation (advanced, first line), which of the standard options do you recommend and why?Why: Guideline options include: Carboplatin and paclitaxel; CAP or platinum-etoposide as alternatives.
- Am I a candidate for Carboplatin, Paclitaxel / nab-paclitaxel, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
After platinum
- For my situation (after platinum), which of the standard options do you recommend and why?Why: Guideline options include: Sunitinib; lenvatinib (approved in Japan, REMORA); pembrolizumab with cardiac and autoimmune monitoring; everolimus; imatinib for KIT-mutant tumours.
- Am I a candidate for Sunitinib, Lenvatinib, Pembrolizumab or related drugs, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
Trials
- For my situation (trials), which of the standard options do you recommend and why?Why: Guideline options include: KC1036, sacituzumab tirumotecan, CAR-NK cells, ramucirumab combinations.
- Am I a candidate for KC1036, EB-CAR30-NK, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of A Study of KC1036 in Patients with Advanced Thymic Tumors and Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Any stage
- Are there clinical trials I could join, for example of Lenvatinib, Sunitinib, Pembrolizumab, KC1036?Why: Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Why: Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Why: Supportive care improves quality of life and helps patients complete treatment.
- I read that “No randomised trial has compared any two regimens in thymic carcinoma”. How does that affect my plan?Why: Open problems are where trials and second opinions matter most.
- I read that “The sequence of kinase inhibitors and immunotherapy is unstudied”. How does that affect my plan?Why: Open problems are where trials and second opinions matter most.
Newly diagnosed? Read the first 60 days with Thymic carcinoma, then print the one-page appointment sheet with room for the answers.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Direct links plus the targets, companies, and technologies of this cancer's products.
technologies
12targets
8drugs
12companies
8terms
3trials
3key papers
4The names on a thymic pathology report, and the sharp line between thymoma and thymic carcinoma that drives treatment, come from this classification.
Lenvatinib is one of the few drugs with prospective evidence in thymic carcinoma after chemotherapy, alongside sunitinib and pembrolizumab.
PD-1 blockade is an option for thymic carcinoma after chemotherapy in expert centres, with close monitoring for myocarditis; it is not used in thymoma because of autoimmunity.
The thymoma and thymic carcinoma pages follow this guideline for who gets surgery, radiotherapy and chemotherapy; its central message is that these rare tumours should be discussed in an expert network.
Latest papers
topQuery for this cancer: (TITLE:"Thymic carcinoma" OR ABSTRACT:"Thymic carcinoma" OR TITLE:"Thymic squamous cell carcinoma" OR ABSTRACT:"Thymic squamous cell carcinoma" OR TITLE:"Type C thymoma obsolete" OR ABSTRACT:"Type C thymoma obsolete" OR TITLE:"Malignant thymic epithelial tumour" OR ABSTRACT:"Malignant thymic epithelial tumour") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Thymic carcinoma, not a curated reading list.
Similar pages
not linked directly; found by shared links- CancerMucosal melanoma
Shares KIT, Imatinib, Cisplatin, PD-1 and the tag subtype-page.
- CancerDermatofibrosarcoma protuberans
Shares Sunitinib, Imatinib, Doxorubicin, IMRT / IGRT (modern external beam) and the tag subtype-page.
- CancerUterine carcinosarcoma
Shares Lenvatinib, Robotic & minimally invasive surgery, Paclitaxel / nab-paclitaxel, Carboplatin and the tag subtype-page.
- CancerLocally advanced cervical cancer
Shares Robotic & minimally invasive surgery, Proton therapy, Paclitaxel / nab-paclitaxel, Cisplatin and the tag subtype-page.
- CancerEarly triple-negative breast cancer
Shares Cyclophosphamide, Doxorubicin, Paclitaxel / nab-paclitaxel, Carboplatin and the tag subtype-page.
- CancerAnaplastic thyroid cancer
Shares Lenvatinib, Doxorubicin, Paclitaxel / nab-paclitaxel, IMRT / IGRT (modern external beam) and the tag subtype-page.
- CancerAdvanced cutaneous squamous cell carcinoma
Shares Tumour mutational burden (TMB), Everolimus, PD-1, Carboplatin and the tag subtype-page.
- CancerAcral melanoma
Shares KIT, Imatinib, PD-1, Small-molecule kinase inhibitors and the tag subtype-page.